paeA Antibody

What is paeA Antibody and what organisms does it target?

The paeA Antibody is a polyclonal antibody developed against the paeA protein found in Escherichia coli. There are two primary variants targeting different E. coli strains: one for E. coli strain K12 (Entrez Gene ID: 948735) and another for E. coli O157:H7 (Entrez Gene ID: 913900, Gene Symbol: ytfL) . These antibodies are typically derived from rabbit hosts (IgG isotype) and demonstrate specificity for bacterial targets. The antibodies recognize recombinant paeA protein, which is used as the immunogen during production. The corresponding UniProt numbers are P0AE45 for E. coli K12 and P0AE47 for E. coli O157:H7 .

What are the standard applications for paeA Antibody in research?

Based on product specifications, paeA Antibody is validated for two primary research applications:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of paeA protein in samples, allowing researchers to measure protein concentrations.

• Western Blot (WB): For qualitative detection and confirmation of paeA protein presence, enabling visualization of the protein based on molecular weight .

The antibody is particularly useful in bacterial research focusing on E. coli strains, especially when studying protein expression, localization, and function of paeA. The polyclonal nature of these antibodies means they can recognize multiple epitopes on the target protein, potentially providing stronger signals in detection applications compared to monoclonal antibodies.

What are the optimal storage conditions for paeA Antibody?

For maintaining optimal antibody activity and stability, paeA Antibody should be stored at either -20°C or -80°C, as indicated in the product specifications . Researchers should adhere to the following storage guidelines:

• Avoid repeated freeze-thaw cycles as they can lead to denaturation and reduced antibody performance

• Prepare small aliquots for working stocks to minimize freeze-thaw cycles

• For short-term use, the antibody can typically be stored at 4°C for up to one week (verify with specific product documentation)

• Protect from light exposure and contamination, which can affect antibody stability and function

Following these storage recommendations will help maintain the antibody's specificity and sensitivity throughout your research project.

How do the different variants of paeA Antibody differ in their specificity and applications?

The two main variants of paeA Antibody target different strains of E. coli with distinct characteristics:

The key differences lie in their target specificity . The K12 variant targets the laboratory strain commonly used in molecular biology research, while the O157:H7 variant targets a pathogenic strain associated with foodborne illness. This distinction is crucial when designing experiments:

• For basic molecular biology research: The K12 variant is typically more appropriate

• For pathogenicity studies or detection of virulent strains: The O157:H7 variant would be preferred

The different purification methods may also affect antibody performance. Antigen-affinity purified antibodies often have higher specificity for the target antigen, while Protein A/G purification selects for all IgG antibodies in the serum .

What are the recommended validation protocols for paeA Antibody in Western Blot applications?

Recommended validation protocols for paeA Antibody in Western Blot applications include:

• Positive Control Validation:

  • Use the recombinant immunogen protein (provided with some antibody products as a positive control, 200μg)

  • Include lysates from E. coli strains known to express paeA

  • Run appropriate molecular weight markers to confirm band size

• Negative Control Validation:

  • Use pre-immune serum (provided with some products as a negative control)

  • Include lysates from bacteria known not to express paeA

  • Consider using knockout or knockdown samples if available

• Protocol Optimization:

  • Test multiple antibody dilutions (typically starting with manufacturer recommendations)

  • Optimize blocking conditions to reduce background

  • Test different detection systems (chemiluminescent vs. chromogenic)

  • Adjust exposure times to achieve optimal signal-to-noise ratio

• Specificity Confirmation:

  • Perform peptide competition assay using the immunizing peptide

  • Conduct side-by-side comparison with alternative antibodies against the same target

  • Consider mass spectrometry validation of the detected band

• Reproducibility Assessment:

  • Perform technical replicates

  • Test across multiple antibody lots if available

  • Validate results across different sample preparation methods

For optimal results, standard Western Blot protocols should be followed, with particular attention to appropriate sample preparation for bacterial proteins, which may require specialized lysis buffers to efficiently extract bacterial proteins.

How can researchers optimize ELISA protocols when using paeA Antibody?

Optimizing ELISA protocols with paeA Antibody involves several key considerations:

• Antibody Titration:

  • Determine optimal primary antibody concentration through serial dilutions

  • Test concentrations ranging from 1:500 to 1:10,000 depending on antibody potency

  • Identify the dilution that provides maximum specific signal with minimal background

• Format Selection:

  • Direct ELISA: Coat plates with sample containing paeA

  • Sandwich ELISA: Use a capture antibody against paeA, then detect with paeA Antibody

  • Competitive ELISA: Pre-incubate paeA Antibody with free antigen before adding to plate

• Buffer Optimization:

  • Test different coating buffers (carbonate/bicarbonate pH 9.6 vs. PBS pH 7.4)

  • Optimize blocking solutions (BSA vs. non-fat milk vs. commercial blockers)

  • Evaluate different wash buffer compositions (PBS-T vs. TBS-T)

• Incubation Parameters:

  • Compare different incubation temperatures (4°C, room temperature, 37°C)

  • Test various incubation times for antibody binding

  • Evaluate plate shaking vs. static incubation

• Detection System:

  • Select appropriate enzyme-conjugated secondary antibody (HRP or AP)

  • Choose optimal substrate (TMB, ABTS, pNPP) based on sensitivity requirements

  • Consider amplification systems for low-abundance targets

When working with bacterial targets like paeA, particular attention should be paid to sample preparation methods that effectively solubilize the target protein without introducing interfering substances.

How can computational models like PARA be applied to predict paeA Antibody binding properties?

Computational models like PARA (Pre-trained model of Antibody sequences trained with a Rational Approach for antibodies) can be valuable tools for predicting antibody-antigen interactions and optimizing antibody applications:

• Sequence-Based Predictions:

  • Use PARA to analyze the antibody's complementarity-determining regions (CDRs)

  • Predict potential binding epitopes on paeA protein

  • Estimate binding affinity based on sequence characteristics

• Structural Modeling Applications:

  • Generate 3D models of antibody-antigen complexes

  • Identify critical residues involved in binding

  • Predict effects of mutations in either antibody or antigen

• Cross-Reactivity Assessment:

  • Compare potential epitopes across related bacterial proteins

  • Identify regions of high similarity that might lead to cross-reactivity

  • Predict off-target binding based on structural similarity

• Implementation Approach:

  • Extract antibody sequence information from the product data

  • Input sequences into PARA or similar computational platforms

  • Run prediction algorithms for binding properties

  • Validate computational predictions experimentally

As described in research, PARA employs "a strategy conforming to antibody sequence patterns and an advanced natural language processing self-encoding model structure" . This approach can capture the unique features of antibody sequences better than general protein modeling tools, making it particularly valuable for predicting paeA Antibody properties and optimizing experimental protocols.

What approaches can resolve inconsistent results when using paeA Antibody across different experimental conditions?

When facing inconsistent results with paeA Antibody, researchers can employ systematic troubleshooting approaches:

• Antibody Validation:

  • Confirm antibody activity using positive controls (recombinant immunogen)

  • Test antibody from different lots to identify lot-to-lot variations

  • Evaluate antibody stability and potential degradation

• Sample Preparation Analysis:

  • Compare different bacterial lysis methods (sonication, bead-beating, chemical lysis)

  • Assess the impact of different buffer compositions on antigen integrity

  • Evaluate the effects of sample storage conditions and freeze-thaw cycles

• Protocol Standardization:

  • Develop detailed standard operating procedures (SOPs)

  • Control for variables like temperature, incubation time, and reagent concentrations

  • Implement internal controls for normalization across experiments

• Interference Identification:

  • Test for matrix effects in complex samples

  • Evaluate potential inhibitors present in different sample types

  • Consider pre-clearing samples to remove interfering substances

• Multi-Method Verification:

  • Confirm results using alternative detection methods

  • Combine Western blot with ELISA or other techniques

  • Use orthogonal approaches (e.g., mass spectrometry) to verify target identity

This systematic approach allows researchers to identify the source of inconsistencies and develop strategies to obtain reliable, reproducible results when working with paeA Antibody across different experimental setups.

How can researchers integrate paeA Antibody studies with modern computational antibody sequence analysis?

Integrating paeA Antibody research with computational antibody sequence analysis offers powerful opportunities for enhanced understanding and application:

• Epitope Mapping and Prediction:

  • Use computational tools to predict antibody binding sites on paeA

  • Employ algorithms that analyze both linear and conformational epitopes

  • Integrate experimental epitope mapping data with computational predictions

• Structural Analysis:

  • Generate antibody-antigen complex models using AlphaFold or similar tools

  • Predict binding energetics and stability of interactions

  • Visualize binding interfaces to understand molecular recognition

• Sequence-Structure-Function Relationships:

  • Correlate antibody sequence variations with functional differences

  • Apply machine learning to predict binding properties based on sequence features

  • Identify critical residues for antibody-antigen interactions

• Implementation Strategy:

  • Start with sequence analysis of the paeA protein to identify potential epitopes

  • Use PARA or similar models to predict antibody binding characteristics

  • Compare predictions with experimental results

  • Refine models based on experimental feedback

As modern antibody research increasingly incorporates computational approaches, researchers can leverage tools like PARA that employ "a strategy conforming to antibody sequence patterns and an advanced natural language processing self-encoding model structure" . This integration creates a powerful framework for advancing antibody research beyond traditional methods.

What methodological considerations are important when using paeA Antibody in multiplex immunoassays?

Implementing paeA Antibody in multiplex immunoassays requires careful methodological planning:

• Compatibility Assessment:

  • Evaluate buffer compatibility across multiple antibodies

  • Test for potential cross-reactivity between antibodies

  • Assess shared secondary antibody requirements

• Optimization of Antibody Panels:

  • Determine optimal concentrations for each antibody in the multiplex

  • Balance signal intensities across different targets

  • Consider using antibodies from different host species to enable distinct detection

• Cross-Reactivity Mitigation:

  • Perform single-plex controls alongside multiplex assays

  • Include absorption controls to verify specificity

  • Consider using monoclonal antibodies for critical targets

• Detection System Selection:

  • Choose detection systems with minimal spectral overlap

  • Consider fluorescent labels with distinct excitation/emission profiles

  • Evaluate quantum dots or other advanced labels for improved separation

• Validation Strategy:

  • Compare multiplex results with single-plex assays

  • Assess precision across replicates and runs

  • Determine limits of detection for each analyte in the multiplex context

When incorporating paeA Antibody into multiplex assays, researchers should first validate it in single-plex format and then gradually incorporate additional targets, carefully monitoring for any interference or cross-reactivity issues. This stepwise approach helps ensure reliable results in the more complex multiplex setting.

What cross-reactivity considerations should researchers be aware of when using paeA Antibody?

Cross-reactivity is an important consideration when working with antibodies against bacterial proteins like paeA:

• Strain-Specific Considerations:

  • The paeA Antibody targeting E. coli K12 may have different reactivity patterns than the one targeting O157:H7

  • Sequence homology between paeA in different E. coli strains should be evaluated

  • Consider testing the antibody against multiple E. coli strains to determine specificity

• Species Cross-Reactivity:

  • While the antibody is validated for bacteria, specific reactivity beyond E. coli may vary

  • Check for potential cross-reactivity with related Enterobacteriaceae family members

  • Sequence alignment of paeA homologs across bacterial species can help predict potential cross-reactions

• Non-Specific Binding:

  • The polyclonal nature of the antibody means multiple epitopes are recognized, potentially increasing non-specific binding

  • Optimize blocking conditions to minimize background

  • Consider additional purification steps if high specificity is required

• Validation Approaches:

  • Western blot analysis against lysates from multiple bacterial species

  • ELISA against purified proteins from related bacteria

  • Pre-adsorption experiments to remove cross-reactive antibodies

  • Competition assays with homologous proteins

• Experimental Controls:

  • Include genetically modified strains lacking paeA as negative controls

  • Use purified recombinant proteins from related bacteria as specificity controls

  • Consider multiple detection methods to confirm specificity

Understanding the potential cross-reactivity profile helps researchers interpret results accurately and design appropriate controls to validate antibody specificity in their specific experimental context.